LOW-molecular-weight-heparin in Radial Artery Occlusion treatment: the LOW-RAO randomized study

Authors: Matthaios Didagelos, Areti Pagiantza, Thomas Zegkos, Christos Papanastasiou, Konstantina Zarra, Vasileios Angelopoulos, Antonios Kouparanis, Emmanouela Peteinidou, George Sianos, Haralambos Karvounis & Antonios Ziakas

Citation: https://www.futuremedicine.com/doi/full/10.2217/fca-2021-0067

Trial registration no.: NCT04196309

STUDY DESIGN

- Prospective
- Single-center
- Open-label
- Randomized (1:1)
- Phase IV study
- 60 patients

KEY ELIGIBILITY CRITERIA

1) Age 18 years

2) Patients (both male and female) undergoing a coronary catheterization procedure (both angiography and/or PCI) through the transradial access for any indication and having successfully received at least one radial artery sheath of any size at the end of the procedure.

3) Radial artery occlusion confirmed by ultrasound (2D, Doppler, color)

≥18

at least 1 radial sheath



OUTCOME MEASURES/ENDPOINTS

Primary endpoints

Radial artery patency at 4 weeks

GLOSSARY

LMWH: Low-molecular-weight-heparin, PCI: Percutaneous coronary intervention, RAO: Radial artery occlusion, u/s: Ultrasound



©2021 Future Medicine Ltd